Lung cancer committee

International Journal of Radiation Oncology Biology Physics

Volumn 51, Issue 3 SUPPL. 2, 2001, Pages 44-52

  Byhardt, R ^a   Komaki, R ^a   Ettinger, D ^a   Johnstone, D ^a   Bradley, J ^a   Franko, A ^a   Gaspar, L ^a   Gillin, M ^a   Langer, C ^a   Layne, E ^a   Movsas, B ^a   Munden, R ^a   Sause, W ^a   Stern, J ^a   Hsu, J ^a   Hartsell, W ^a   Yesner, R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AMIFOSTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA INTERFERON; CAPTOPRIL; CARBOPLATIN; CISPLATIN; DOCETAXEL; ENOXAPARIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 6; IRINOTECAN; ISOTRETINOIN; PACLITAXEL; PROTEIN P53; SELENIUM; SURFACTANT; TIRAPAZAMINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; VASCULOTROPIN;

ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; REVIEW; SECOND CANCER; ARTICLE; FORECASTING; LUNG TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; SMALL CELL CARCINOMA; TREATMENT FAILURE;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; LUNG NEOPLASMS; ORGANIZATIONAL OBJECTIVES; PROFESSIONAL STAFF COMMITTEES; RADIATION ONCOLOGY; RESEARCH DESIGN; TREATMENT FAILURE;

EID: 85047686552     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01779-5     Document Type: Article

References (25)

1. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer
2. Postoperative radiotherapy in non-small cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomized controlled trials
3. Effects of postoperative mediastinal irradiation on completely resected stage II and stage III epidermoid cancer of the lung
4. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a Phase III study (RTOG 94-10)
5. Phase III comparison of sequential vs. concurrent chemo-RT: Initial report of RTOG 94-10
6. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer
7. A randomized phase II trial of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemo-radiotherapy for unresectable stage III non-small cell lung cancer
8. Impact of local control on survival
9. The impact of radiation dose and fractionation on the risk factor of radiation pneumonitis on four Radiation Therapy Oncology Group (RTOG) lung cancer trials
10. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemo-radiation studies
11. Combined Betaseron (recombinant human interferon beta), and radiation for inoperable non-small cell lung cancer
12. Recursive partitioning analysis of 1,592 patients on four RTOG studies in inoperable NSCLC
13. Prolonged survival in pathologic stage IIIB non-small cell lung cancer with concurrent chemoradiotherapy followed by consolidation docetaxel: A phase II study (S9504) of the Southwest Oncology Group (SWOG)
14. Randomized Phase III study of irinotecan (CPT-11), and cisplatin versus etoposide, and cisplatin in extensive disease small cell lung cancer
15. Hyperfractionated radiotherapy of human tumors: Overview of the randomized clinical trials
16. Age dramatically impacts on the quality-adjusted time without symptoms of toxicity (Q-Twist) in locally advanced non-small cell lung cancer - A Radiation Therapy Oncology Group (RTOG) analysis
17. Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC
18. Chemoradiotherapy for poor-risk stage III non-small cell lung cancer
19. Comorbidity and functional status are independent in older cancer patients
20. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in RTOG 88-08/ECOG 4588
21. Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): Analysis of Radiation Therapy Oncology Group (RTOG) Trials. Eighth World Conference on Lung Cancer
22. Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1,547 on four Radiation Therapy Oncology Group (RTOG) studies in operable non-small cell lung cancer (NSCLC)
23. Prophylactic cranial irradiation in locally advanced non-small cell lung cancer after multimodality treatment: Long term follow-up and investigation of late neuropsychologic effects
24. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission: A meta-analysis of individualized data from 987 patients
25. A trial comparing hyperfractionated prophylactic cranial irradiation versus no prophylactic cranial irradiation in patients with limited stage small cell lung cancer with complete response to chemotherapy and consolidative radiotherapy